News

Filter

Current filters:

Kalydeco

1 to 9 of 26 results

Royalty Pharma pays $3.3 billion for CFF royalty rights to Kalydeco

19-11-2014

Royalty Pharma says it has acquired royalties on Vertex Pharmaceuticals' cystic fibrosis treatments,…

BiotechnologyFinancialKalydecoRare diseasesRoyalty PharmaVertex Pharmaceuticals

Australian PBS listing for Kalydeco and Soliris

Australian PBS listing for Kalydeco and Soliris

27-10-2014

Kalydeco (ivacaftor) and Soliris (eculizumab) – new treatments for cystic fibrosis (CF) and hemolytic…

Alexion PharmaceuticalsAustraliaFinancialHealthcareKalydecoPharmaceuticalRare diseasesSolirisVertex Pharmaceuticals

FDA advisory backs expanded use of Vertex’ CF drug

22-10-2014

There was good news for US biotech firm Vertex Pharmaceuticals yesterday, as a US Food and Drug Administration…

BiotechnologyKalydecoRare diseasesRegulationUSAVertex Pharmaceuticals

Report: Global cystic fibrosis market value to treble by 2019

12-03-2014

The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

FDA backs Kalydeco for eight additional mutations that cause cystic fibrosis

22-02-2014

The US Food and Drug Administration approved biotech firm Vertex Pharmaceuticals’ supplemental New…

BiotechnologyKalydecoNorth AmericaRare diseasesRegulationUSAVertex

1 to 9 of 26 results

COMPANY SPOTLIGHT

Menarini

Back to top